# Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

> **NCT05704621** · PHASE2 · RECRUITING · sponsor: **Korea University Guro Hospital** · enrollment: 124 (estimated)

## Conditions studied

- Ovarian Cancer
- Drug Related Neoplasm/Cancer

## Interventions

- **PROCEDURE:** secondary cytoreductive surgery
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT05704621
- **Lead sponsor:** Korea University Guro Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-12-28
- **Final completion:** 2028-12-28
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704621, "Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05704621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*